Efficacy and safety of treatment of hepatitis c in patients with inflammatory bowel disease

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 12, 2013, Pages 1655-1660.e1

  Allen, Alina M ^a   Kim, W Ray ^a   Larson, Joseph ^a   Loftus, Edward V ^a  

^a MAYO CLINIC   (United States)

Author keywords

CD; Inflammation; SVR; UC

Indexed keywords

ALPHA2A INTERFERON; AZATHIOPRINE; BUDESONIDE; ENEMA; ETANERCEPT; MERCAPTOPURINE; MESALAZINE; PEGINTERFERON ALPHA; PLACEBO; PREDNISOLONE; RIBAVIRIN; TELAPREVIR; TUMOR NECROSIS FACTOR INHIBITOR; VIRUS RNA;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CELL LINEAGE; CLINICAL ARTICLE; COLONOSCOPY; CROHN DISEASE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HISTOLOGY; HUMAN; LEUKOPENIA; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; META ANALYSIS; MONOTHERAPY; PANCYTOPENIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT RESPONSE; ULCERATIVE COLITIS; VIRAL CLEARANCE;

6-MERCAPTOPURINE; 6-MP; 6-TGN; 6-THIOGUANINE NUCLEOTIDE; AZA; AZATHIOPRINE; CD; CROHN'S DISEASE; HCV; HEPATITIS C VIRUS; IBD; IFN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTERFERON; PEGIFN; PEGYLATED INTERFERON; SUSTAINED VIROLOGIC RESPONSE; SVR; UC; ULCERATIVE COLITIS;

ADULT; AGED; ANTIVIRAL AGENTS; ENDOSCOPY; FEMALE; HEPATITIS C; HISTOCYTOCHEMISTRY; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERONS; MALE; MIDDLE AGED; MINNESOTA; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84887998123     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.07.014     Document Type: Article

References (48)

1. Berenguer M., Ferrell L., Watson J., et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. JHepatol 2000, 32:673-684.
2. Peyrin-Biroulet L., Cadranel J.F., Nousbaum J.B., et al. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Ther 2008, 28:984-993.
3. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997, 112:1017-1021.
4. Fuss I.J., Heller F., Boirivant M., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. JClin Invest 2004, 113:1490-1497.
5. Tilg H., Vogelsang H., Ludwiczek O., et al. Arandomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003, 52:1728-1733.
6. Madsen S., Schlichting P., Davidsen B., et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001, 96:1807-1815.
7. Bargiggia S., Thorburn D., Anderloni A., et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis Cand inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther 2005, 22:209-215.
8. Sumer N., Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995, 7:597-602.
9. Cottone M., Magliocco A., Trallori G., et al. Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis. Ital J Gastroenterol 1995, 27:3-4.
10. Scherzer T.M., Staufer K., Novacek G., et al. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. Aliment Pharmacol Ther 2008, 28:742-748.
11. Katsanos K., Tsianos V., Zois C., et al. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. JCrohns Colitis 2010, 4:450-465.
12. Miike T., Tahara Y., Yamaguchi Y., et al. [A case study: interferon-beta-induced remission of ulcerative colitis in a patient with type C chronic hepatitis]. Jpn J Gastroenterol 2008, 105:1362-1366.
13. Sprenger R., Sagmeister M., Offner F. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut 2005, 54:438-439.
14. Villa F., Rumi M.G., Signorelli C., et al. Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. Eur J Gastroenterol Hepatol 2005, 17:1243-1245.
15. Awakawa T., Hirohashi S., Hasegawa K., et al. [A case of acute phase ulcerative colitis like colitis developed by the interferon-beta therapy for chronic hepatitis C]. Jpn J Gastroenterol 2003, 100:680-684.
16. Niki T., Nishida K., Honsako Y., et al. [A case of ulcerative colitis along with characteristic features on computed tomography (CT), developed by the treatment with interferon for chronic hepatitis C]. Jpn J Gastroenterol 2001, 98:399-404.
17. Mavrogiannis C., Papanikolaou I.S., Elefsiniotis I.S., et al. Ulcerative colitis associated with interferon treatment for chronic hepatitis C. JHepatol 2001, 34:964-965.
18. Usami T. Interferon induced ulcerative colitis-like acute colitis. Rinshohinyokika 1999, 53:54-57.
19. Honda K. Acase of incidence of ulcerative colitis during the therapy of interferon for hepatitis C 1993, Nippon Shokakibyo Gakkai Zasshi, 90:1085.
20. Watanabe T., Hirono H., Hasegawa K., et al. Literature review in cases with exacerbation of ulcerative colitis induced by treatment with interferon and/or ribavirin. JGastroenterol Hepatol 2011, 26:1709-1716.
21. Salguiero P., Lago P., Pedroto I. Diagnosis of inflammatory bowel disease in chronic hepatitis C patients treated with pegylated interferon and ribavirin: coincidence or consequence?. JCrohns Colitis 2013, 7:194.
22. Efe C., Roach E.C., Purnak T., et al. Chronic hepatitis C, inflammatory bowel disease and interferon therapy. JCrohns Colitis 2012, 6:626-627.
23. Tursi A. Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C. Inflamm Bowel Dis 2007, 13:1189-1190.
24. Altnbas A., Koybasoglu F., Aktas E., et al. Ulcerative colitis triggered by pegylated interferon alone therapy for chronic hepatitis C. Inflamm Bowel Dis 2011, 17:1050.
25. Bongiovanni M., Ranieri R., Ferrero S., et al. Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin. AIDS 2006, 20:1989-1990.
26. Khalil A., Lucidarme D., Desurmont P., et al. [Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C]. Gastroenterologie clinique et biologique 2005, 29:193-196.
27. Yamamoto Y., Sakatani N., Yano S., et al. [Interferon induced IBD-like acute colitis: two cases of patients with chronic active hepatitis]. Jpn J Gastroenterol 1995, 92:1293-1296.
28. Watanabe T., Inoue M., Harada K., et al. Acase of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin. Gut 2006, 55:1682-1683.
29. Mitoro A., Yoshikawa M., Yamamoto K., et al. Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med 1993, 32:327-331.
30. Abdelmalek M.F., Liu C., Valentine J.F. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in apatient with Crohn's disease. Am J Gastroenterol 2007, 102:1333-1334.
31. Salcedo-Mora X., Mate J., Medina J., et al. Chronic hepatitis C andCrohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin. Digestion 2006, 73:210-214.
32. Sawada K., Ohnishi K., Kusaka T., et al. Dramatic response to granulocytapheresis in a Crohn's disease case complicated by hepatitis C virus. Dig Dis Sci 2005, 50:1533-1534.
33. Sawada K., Ohnishi K., Fukunaga K., et al. Anew treatment for HCV-ulcerative colitis comorbidity intolerant to INF-alpha. Am J Gastroenterol 2003, 98:228-229.
34. Campbell S., Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001, 13:191-192.
35. De Diego Lorenzo A., Kashoob M., Romero M., et al. [Treatment with recombinant interferon alfa-2b of a patient with chronic hepatitis C and concomitant ulcerative colitis]. Revista espanola de enfermedades digestivas 1997, 89:399-401.
36. Derijks L.J., Gilissen L.P., Hooymans P.M., et al. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006, 24:715-729.
37. Gish R.G. Treating HCV with ribavirin analogues and ribavirin-like molecules. JAntimicrob Chemother 2006, 57:8-13.
38. Biancone L., Del Vecchio Blanco G., Pallone F., et al. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 2002, 122:593-594.
39. Lin A., Thadareddy A., Goldstein M.J., et al. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. JMed Virol 2008, 80:1720-1722.
40. Magy N., Cribier B., Schmitt C., et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999, 21:253-261.
41. Klintmalm G.B., Davis G.L., Teperman L., et al. Arandomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011, 17:1394-1403.
42. Stangl J.R., Carroll K.L., Illichmann M., et al. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation 2004, 77:562-567.
43. Samonakis D.N., Germani G., Burroughs A.K. Immunosuppression and HCV recurrence after liver transplantation. JHepatol 2012, 56:973-983.
44. Fukuda R., Ishimura N., Ishihara S., et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996, 16:390-399.
45. Zein N.N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. JHepatol 2005, 42:315-322.
46. Peterson J.R., Hsu F.C., Simkin P.A., et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003, 62:1078-1082.
47. Lin M., Blonski W., Buchner A., et al. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig Dis Sci 2013, 58:1149-1156.
48. McHutchison J., Lawitz E., Shiffman M., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. NEngl J Med 2009, 361:580-593.